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Background: Patients with sickle cell disease (SCD) have a high
risk of intracranial large vessel vasculopathy. This can lead to
a proliferation of microvasculature at the base of the brain known
as moyamoya syndrome. If untreated, there is a high risk of intra-
ventricular hemorrhage and permanent neurologic deficits. There
have been several reports describing patients with SCD and
moyamoya syndrome successfully undergoing revascularization
procedures, including encephaloduroarteriosynangiosis (EDAS).
Hematopoietic cell transplantation from a compatible sibling is
the most effective way of preventing central nervous system
(CNS) complications in SCD patients at risk for CNS events.
To our knowledge, there have been no reports of SCD patients
undergoing EDAS followed by bone marrow transplantation
(BMT).
Case:We describe the case of a 14-year-old girl with SCD who de-
veloped severe stenosis of the right internal carotid artery, which
progressed and extended to the anterior cerebral andmiddle cerebral
arteries, with silent infarcts and changes on magnetic resonance an-
giography (MRA) consistent with moyamoya syndrome. Due to
worsening of her stenosis, at the age of 11 she underwent EDAS
without complications. Eighteenmonths after the procedure, she de-
veloped a left lower extremity monoparesis. Magnetic resonance im-
aging (MRI) did not show any new areas of ischemia. Three months
later she underwent high-dose chemo-immunotherapy followed by
BMT from her compatible sibling. Her mixed-donor chimerism
on day +32 was 98% donor, with concomitant hemoglobin S of
0.9%, confirming donor engraftment and eradication of her SCD.
The patient is now 10 months post-transplant and has not had any
SCD-related complications. Her neurologic exam and neuroimag-
ing studies remain stable.
Conclusion: This is the first case report of EDAS successfully fol-
lowed by BMT in a patient with SCD and moyamoya syndrome.
BMT is considered standard of care in patients with SCD at risk
for CNS complications, leading to stroke-free survival rates of 93-
96%. Patients with moyamoya syndrome and SCD who have
a CNS event are more than twice as likely to experience a recurrent
CNS complication even while on chronic transfusions. Transplant-
eligible SCDpatients who developmoyamoya syndromemay benefit
from EDAS prior to undergoing BMT in order to minimize peri-
and post-transplant CNS complications. Further investigation is
needed to determine the long-term outcome of this therapeutic com-
bination.317
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Introduction: Hemorrhagic cystitis (HC) is a common complica-
tion after haematopoietic stem cell transplantation (HSCT).
Urotropic viruses may cause late-onset HC (BK virus {BKV}, adeno-virus, CMV) associated with severe immunosuppression. Treatment
is mainly symptomatic. The incidence and severity of HC depends
on primary disease, pre-transplant viral status, conditioning, immu-
nosuppressive drugs, source of graft and Graft-versus-Host Disease.
Objectives:: to review the incidence, severity, treatment and
outcome of BKV associated HC post HSCT.
Methods: Patients with BKV associated HC were identified retro-
spectively, reviewing electronic charts of all hospitalized children
in 2004-2010. Diagnosis of BKV is made by a standard Blood and
urine PCR method.
Results: BKV associated HC developed in 11children, during the
study period. One patient had primary immune deficiency and
lymphoma. There were 42 patients with autologous BMT, none
of them had HC. In 10/81 (12%) HC developed after allogeneic
HSCT. Nine patients received Antithymoglobulin (ATG) in com-
bination with high dose of Cyclophosphamide, steroids or total
body irradiation and developed symptoms of HC in the first 3
months after BMT. In 5/10 children Blood CMV reactivation oc-
curred concomitantly. The last 3 patients were treated with low
dose cidofovir (1mg/kg) weekly and 1 patient received a combina-
tion of parenteral and intravesicular cidofovir with an excellent ef-
fect consisting of rapid clinical recovery after 2 doses and
significant decreasing of BK viral load in blood and urine without
side effects. The improvement was more prominent with tapering
down of immune suppressive medications and immune reconstitu-
tion after HSCT.
Conclusion:BKHC is a severe complication after allogeneicHSCT
children. ATG combined with TBI or Cyclophosphamide is a signif-
icant risk factor. Low dose cidofovir could be the option for the treat-
ment of BK infection in combination with symptomatic treatment
until immunological recovery after HSCT.318
REDUCED INTENSITY CONDITIONING FOR SECOND HEMATOPOIETIC
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Reduced-intensity conditioning (RIC) regimens have extended
the availability of allogeneic hematopoietic cell transplantation
(HCT) to a large group of previously ineligible adult patients with
hematological malignancies. To address whether this is a feasible ap-
proach for secondHCT in children with relapsed acute myeloid leu-
kemia (AML) following allogeneic HCT, we evaluated outcomes of
patients with AML transplanted using RIC at our center, between
2005-2010.
Nine out of total 10 patients with relapsed AML following al-
logeneic HCT were in CR2 or higher disease status at the time
of second HCT (table). Type of grafts included bone marrow
(5), peripheral blood stem cells (1), and umbilical cord blood
(4), that were obtained from matched unrelated donors in 9 pa-
tients and matched sibling donor in 1. All patients received RIC
containing Fludarabine 25mg/m2 from day-8 through Day-4
and Melphalan 140mg/m2 on day -3. One patient with baseline
chromosomal sensitivity was transplanted in CR1, with 50% re-
duction in Melphalan dose (70mg/m2). Graft versus host disease
(GVHD) prophylaxis included cyclosporine (CSA) and Mycophe-
nolate mofetil (MMF) in 7 patients, CSA with steroids in 1 and
tacrolimus with MMF in remaining 2 patients.
All 10 patients tolerated the RIC well without any major compli-
cations or organ dysfunction. All achieved sustained neutrophil en-
graftment, and 9/10 achieved platelet engraftment. Serious
infections included Candida fungemia (2 patients), that responded
well to antifungal therapy. At a median follow-up of 41.4 months
(range 2.5-56.3), 5 patients are alive, and remain disease free, includ-
ing all 4 patients who developedGVHD (Table) and the patient with
underlying chromosomal sensitivity. Of note, 3 of these patients have
S270 Poster Session Ibeen in sustained remission for 41.4 to 56.3 months (3.45 to 4.7
years). Four patients died from relapsed disease at a median of 14.9
months (range 7.73-42) post-HCT, and one with failure to achieve
platelet engraftment, died from pulmonary hemorrhage at 4.5
months post-HCT.Table 1. RIC HCT for relapsed AML - Characteristics and
Results
Number (Range)
Total number of patients 10
Age (yrs), median 5.2 (1.8 – 10.6)
Lansky performance score $ 90 10
Disease status prior to HCT
CR1 1
CR2 3
CR3 3
Active disease 3
Neutrophil engraftment (ANC>500)
in days, median
16.5 (10-40)
Platelet engraftment (Plts >50,000)
in days, median
39 (16-42)
Acute GVHD, grades II-IV 4
Chronic GVHD (extensive) 1
Relapse 4
Time to relapse in days, median 114 (50-144)
Alive at last follow-up 5Overall survival was 61% (95% CI 37-100%) at 1 year and 51%
(95% CI 28-94%) at 3 years post-HCT. Disease free survival
was 42% (95% CI 20-87%) at 1 year and 31% (95% CI 13-
79%) at 3 years post-HCT. This modest success in our small co-
hort, indicate that RIC HCT can achieve long term and durable
remissions in patients with relapsed AML after first HCT, and of-
fer a potentially life-saving treatment option to this group of high
risk patients.SOLID TUMORS
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IMPROVING T-CELL IMMUNOTHERAPIES FOR SOLID TUMORS BY TAR-
GETING THE TUMOR STROMA
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Background: Recent findings indicate that the tumor stroma is
a critical barrier for effective T-cell immunotherapies and that
eradicating the tumor stroma in addition to cancer cells has the po-
tential to increase antitumor effects. Cancer associated fibroblasts
(CAFs) are the central component of the tumor stroma and express
fibroblast activation protein (FAP), which is an attractive immuno-
therapeutic target since it is not expressed in normal tissues. The
objective of this project is to develop an adoptive immunotherapy
approach with antigen-specific T cells targeting FAP expressed on
reactive tumor stroma in addition to tumor antigens expressed on
cancer cells.
Methods:We constructed a FAP-specific chimeric antigen receptor
(CAR) using a FAP-specific single chain variable fragment that rec-
ognizes murine as well as human FAP. Mitogen activated T cells
were transduced with a retroviral vector encoding a second genera-
tion FAP-specific CAR with a CD28.zeta-signaling endodomain
(FAP-T cells).We then performed functional studies to characterize
the generated FAP-T cells.Results: FAP-T cells recognized and killed K562 cells genetically
modified to express FAP in contrast to non-transduced T cells
confirming specificity. FAP-T cells also recognized and killed a panel
of FAP-positive solid tumor cell lines (head and neck cancer, osteo-
sarcoma, breast cancer, andmelanoma). To evaluate if targeting only
the tumor stroma in vivo leads to a reduction of tumor growth we
took advantage of LCLs, which are FAP negative. Luciferase-ex-
preesing LCL were mixed with FAP-T cells, which recognize mu-
rine and human (mhFAP) or human FAP (hFAP), or non-
transduced T cells prior to s.c. injection into flanks of SCID mice.
While LCLs tumor readily established in mice injected with LCL/
hFAP-T cells or LCL/NT-T cells; LCL tumors either did not es-
tablish or their growth was markedly retarted (10- to 100-fold) in
mice injected with LCL/mhFAP-T cells as judged by serial biolumi-
nescence imaging.
Conclusion:We have constructed a FAP-specific CAR that enables
the rapid generation of FAP-T cells for targeting CAFs, the central
component of the tumor stroma. Targeting CAFs with FAP-T cells
resulted in marked reduction in tumor establishment and growth in
vivo. Experiments are in progress to evaluate if cotargeting tumor
cells and their supporting stroma results in enhanced tumor eradica-
tion.320
DOSE-DEPENDENT AND EPITOPE-SPECIFIC IN VIVO IRRADICATION OF
THE HUMAN OVARIAN CARCINOMA CELLS EXPRESSING THE WILLMS
TUMOR PROTEIN, WT1, IN NOD/SCID MICE, BY WT1 SPECIFIC T CELLS
MONITORED BY BIOLUMINESCENT IMAGING
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WT1 is expressed in 60-80% of acute leukemias and ovarian ade-
nocarcinomas. Its expression has been hypothesized to be critical for
the growth or survival of tumorigenic stem cells. Previously, allor-
eactive HLAA0201- T cells recongizing a complex of WT1-peptide
andHLA-A0201were reported to prevent growth of leukemicHLA-
A0201+CD34+Ph+CML progenitor cells in NOD/SCID mice. In
this study, we have assessed the capacity of WT1 CTLs lacking
the alloreactivity, restricted by different HLA alleles and WT1 de-
rived epitopes to prevent the outgrowth of two human ovarian ade-
nocarcinoma cells (OvCar) with low (13%) and high (43%)
expression of WT1 by FACS in NOD/SCID mice. For this study
epitope-specific and HLA restricted WT1-CTLs were generated
from PBMC of four normal donors by in vitro sensitization with au-
tologous EBV transfomed B cells (BLCL) loaded with the pool of
141 15-mers overlapping by 11aa and spanning the entire sequence
of WT1 protein. Each of the T cell lines was pre-incubated in vitro
for 8 hours at different E:T ratios (0:1, 5:1, 10:1, 50:1, 100:1) with
0.05x10^6 OvCar tumor cells transduced to express a luciferase re-
porter gene. The cell mixtures were injected i.p. into NOD/SCID
mice. Tumor growth was monitored weekly by the intensity of the
bioluminescent signal. In all animals injected with the tumor cells
alone the bioluminescent signal could be detected in the abdomen
by day 10-15 and increased steadily through 60 days of observation
(when all these mice died) while tumor engraftment was either mark-
edly inhibited (in OvCarWT1low) or completely abrogated (in Ov-
CarWT1high) by pre-incubation at 100:1 E:T ratio and correlated
with higher survival of the animals (80%) over a period of 120
days. The animals injected with the tumor cells preincubated with
the WT1-CTLs at 50:1 and 10:1 E:T ratio demonstrated weaker
bioluminescent signal in the abdomen which increased over the
course of the study while the pre-incubation of the tumor cells
with WT1-CTL at 5:1 ratio did not significantly affect tumor en-
graftment and growth. The inhibition of tumor growth was more ef-
ficient with the WT-CTL specific for the 398-506LKTHTTRTHT
epitope presented on the A0201 allele as compared to the A0301
or B0702 epitope ((-125)-(-117) RQRPHPGAL). These results suggest
that tumorigenic OvCar cells containing high propotion of WT1+
cells are succeptible to eradication in vivo by high doses of WT1-
CTL specific only for some but not every WT1 epitope selected
by T cells.
